Tom Schoenherr

Tom Schoenherr is CEO of Diagnostics at Tempus AI, the publicly traded precision-medicine company. He previously ran Ambry Genetics as CEO from 2021 to 2025, steering it through a definitive agreement to be acquired by Tempus. He has spent more than 25 years inside molecular diagnostics, with prior leadership stints at Counsyl, Quest Diagnostics, Siemens Healthcare, Abbott Diagnostics, and Omada Health.